![ciara like a boy ddr ciara like a boy ddr](https://static.wikia.nocookie.net/dancedancerevolutionddr/images/a/ab/Baby_img1.gif)
![ciara like a boy ddr ciara like a boy ddr](https://i.ytimg.com/vi/2ZhnxoWyunU/hqdefault.jpg)
![ciara like a boy ddr ciara like a boy ddr](https://i.pinimg.com/originals/5a/01/93/5a0193526ab8eaf275bf2b90e848d79b.jpg)
Treatment with 5.0 mCi of 177Lu-DOTA-TATE increased median survival by 75.0% compared with the saline control group while a single dose of 3.0 mCi 177Lu-DOTA-TATE increased median survival compared with saline controls by 519.4%. RESULTS: Treatment with 2 mCi resulted in an increase in median survival of 58.3% compared with saline control (p < 0.001). Animals were followed 300 days for survival. dose of 2, 3, or 5 mCi of 177Lu- DOTA-TATE or saline control. Groups of 10 animals received a single i.t. METHODS: The subarachnoid space was accessed through the animal's cervical spine and a catheter was threaded along the dorsal aspect of spinal cord to the lumbar region and injected with 1 x 10 7 D341 human MBL cells and treatment initiated 3 days later. 177Lu-DOTA-TATE in athymic rats bearing LMD from MBL. As a preliminary step prior to testing this agent in children with LMD, we performed an efficacy study of i.t. Somatostatin receptor-2 (SSR-2)is overexpressed in medulloblastoma and other central PNETs and can serve as a target for radionuclide tagged somatostatin analogues like 177Lu-DOTA-TATE that has shown considerable efficacy in adults with SSR-2 positive neuro-endocrine tumors. BACKGROUND: LMD in children with recurrent medulloblastoma and other PNETs carries a poor prognosis and novel therapies are urgently needed to improve disease control.